Ascendis Pharma Trial Wins And Valuation Gap Draw Investor Attention [Yahoo! Finance]
Ascendis Pharma A/S - American Depositary Shares (ASND)
Last ascendis pharma a/s - american depositary shares earnings: 11/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ascendispharma.com
Company Research
Source: Yahoo! Finance
Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Ascendis Pharma reported positive Week 52 data for once weekly TransCon hGH in prepubertal children with Turner syndrome. The company also released new Week 104 outcomes for TransCon CNP, branded as YUVIWEL, in children with achondroplasia. YUVIWEL is already approved by the FDA, with an EU submission planned. This highlights growing regulatory momentum around these pediatric programs. For investors tracking NasdaqGS:ASND, these back to back trial readouts add fresh clinical detail around two core pediatric endocrine and rare disease assets. The stock trades at $221.88, with a 1 year return of 33.7% and a 3 year return of 111.5%, indicating that the market has already reacted strongly over a multi year period to the company story. The 5 year return of 69.6% and year to date gain of 4.0% provide additional context for how recent data arrives on top of an already meaningful performance hist
Show less
Read more
Impact Snapshot
Event Time:
ASND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASND alerts
High impacting Ascendis Pharma A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ASND
News
- New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52 [Yahoo! Finance]Yahoo! Finance
- New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52GlobeNewswire
- Ascendis Pharma A/S (ASND) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.MarketBeat
- New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026GlobeNewswire
- Pharma Leaders Discuss Managing Revenue Management System Updates at Model N Rainmaker Panel Hosted by RevSavvyPR Newswire
ASND
Earnings
- 2/11/26 - Miss
ASND
Sec Filings
- 3/18/26 - Form 3
- 3/18/26 - Form 3
- 3/18/26 - Form 3
- ASND's page on the SEC website